Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11506 | 1.00 | NUDT1 (0.53) | NUDT1AXLPRKCINOS1PIK3CD | |
| SCHEMBL9933985 | 0.75 | NUDT1 (0.49) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL3375875 | 0.75 | PRKCI (0.52) | NUDT1AXLPRKCINOS1PIK3CD | |
| SCHEMBL2112472 | 0.75 | PIK3CD (0.46) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL29487195 | 0.75 | XDH (0.53) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL2619223 | 0.75 | CHEK1 (0.47) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL290117 | 0.75 | NOS1 (0.47) | NUDT1NOS1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL29506132 | 0.75 | NOS1 (0.47) | NUDT1NOS1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL21855766 | 0.75 | PIK3CD (0.46) | NUDT1PIK3CDPIK3CAPIK3CBXDH | |
| SCHEMBL1835481 | 0.75 | XDH (0.53) | NUDT1PIK3CDPIK3CAPIK3CBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055363-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | disclosed |
| WO-2024220747-A2 | FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4436957-A1 | THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118302411-A | Therapeutic indazole compounds and methods of use thereof for the treatment of cancer | 基因泰克公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118201915-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-117642411-A | Small molecule CD73 antagonists and uses thereof | 西藏海思科制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116003406-B | Heteroaryl ring nitroxide compound and preparation method and application thereof | 北京鞍石生物科技有限责任公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023097195-A1 | THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| CN-116075307-A | Pyridooxazine amino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116003406-A | Heteroaryl ring nitroxide compound and preparation method and application thereof | 北京鞍石生物科技有限责任公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115835910-A | Hydrogenated isoquinoline or naphthyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-03-21 | — | — | US | disclosed |
| WO-2022159745-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376099-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | TLR3, TLR1, TLR4 | NUDT1 1770/4885AXL 1116/4885PRKCI 1473/4885 |
| US-11608347-B2 | Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors | PYM1, MAG, MAGI3 | NUDT1 1230/4885AXL 4252/4885PRKCI 3547/4885 |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | BTK, SYK, LCK | NUDT1 3286/4885AXL 82/4885PRKCI 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.